Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

Targeting the mTOR Pathway in Leukemia

(2016) Shira Dinner et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) C. X. Ma et al.   CLINICAL CANCER RESEARCH

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia

(2015) Matteo Allegretti et al.   Scientific Reports

Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways

(2014) Stefan Gröschel et al.   BLOOD

A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression

(2014) Hiromi Yamazaki et al.   CANCER CELL

A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

(2014) Stefan Gröschel et al.   CELL

Role of PRAS40 in Akt and mTOR signaling in health and disease

(2012) Claudia Wiza et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins

(2011) A. Yoshimi et al.   BLOOD

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

(2009) Alberto M Martelli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia

(2009) N Gallay et al.   LEUKEMIA

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD